INDEX symptoms

Significant positive associations were observed between the prevalence of each index symptom (headache, nausea, eye and throat irritation) and both frequency of odour perception and degree of worry. Elimination of secondary worry respondents did not affect these relationships. Relationships were strongest for worry rather than odour. In addition to their individual effects, odour and worry exhibited a positive interaction that, in the case of headaches, was almost multiplicative. The authors concluded that worry and odour perception had a potential role in the development of symptoms near hazardous waste sites. 

Improvements in asthma treatment include the development of more effective, safer formulations of known dmgs. The aerosol adrninistration of P2-agonists or corticosteroids results in a decrease in side effects. Also, the use of reUable sustained release formulations has revolutionized the use of oral xanthines which have a very narrow therapeutic index (see Controlled release technology). For many individuals, asthma symptoms tend to worsen at night and the inhaled bronchodilatots do not usually last through an entire night s sleep (26,27). 

Figure 4.4 The general protocol for information extraction from an herbal text (A-E) is paired with case examples from our work with the Ambonese Herbal by Rumphius. (A) Text is digitized. (B) Through either manual reading or automated extraction the plant name(s), plant part(s), and symptoms or disorders are identified. (C) These extracted data are then updated (as necessary) to reflect current names of the plants, using the International Plant Names Index (IPNI), and the pharmacological function(s) of the described medicinal plants are extrapolated from the mentioned symptoms and disorders. (D) The current botanical names are queried against a natural products database such as the NAPRALERT database to determine whether the plant has been previously examined. (E) Differential tables are generated that separate the plants examined in the literature from plants that may warrant further examination for bioactivity. (Adapted from Trends in Pharmacological Sciences, with permission.) See color plate.

Incorporating the Kirtas system with the International Plant Names Index and SNOW-MED allows movement of the historic text into an electronic format, identihcation of current plant names, and identihcation of the symptoms treated with the plants. To complete the mining of historic herbal texts for novel drug leads we use the Natural Products Alert (NAPRALERT ) database to compare the information extracted from the historic herbal text to the reports of plant use in the current literature. The NAPRALERT database provides a summary of plants ethnopharmacological use, biochemical activities, and isolated compounds [27]. By querying each plant (with the current plant name) it is possible to identify any reports in the current literature regarding the plant. As an example, Table 4.1 shows the NAPRALERT output for Cycas rumphii. 

Monitor the patient for the drug s effectiveness in relieving symptoms by using the AUA Symptom Scoring Index. Monitor ensure that the score improves and that the patient subjectively feels that symptoms have improved. 

One of the most sensitive systems affected by lead exposure is the nervous system. Encephalopathy is characterized by symptoms such as coma, seizures, ataxia, apathy, bizarre behavior, and incoordination (CDC 1985). Children are more sensitive to neurological changes. In children, encephalopathy has been associated with PbB levels as low as 70 pg/dL (CDC 1985). The most sensitive peripheral index of neurotoxicity of lead is reported to be slowed conduction in small motor libers of the ulnar nerve in workers with 30-40 pg/dL lead in blood (Landrigan 1989). Other potential biomarkers of lead suggested for neurotoxicity in workers are neurological and behavioral tests, as well as cognitive and visual sensory function tests (Williamson and Teo 1986). However, these tests are not specific to elevated lead exposure... 

ROCK C L, THORNQUIST M D, KRISTAL A R, PATTERSON R E, COOPER D A, NEUHOUSER M L, neumark-sztainer D and cheskin l j (1999), Demographic, dietary and lifestyle factors differentially explain variability in serum carotenoids and fat-soluble vitamins baseline results from the sentinel site of the Olestra Post-Marketing Surveillance Study , J Nutr, 129(4), 855-64. rodale (1996), The Prevention Index - a report card on the nation s health, 1996 summary report. Rodale Press, Inc, Emmaus, Pennsylvania. SANDLER R S, ZORICH N L, FILLOON T G, WISEMAN H B, LIETZ D J, BROCK M H, ROYER M G and MIDAY R K (1999), Gastrointestinal symptoms in 3181 volunteers ingesting snack foods containing olestra or triglycerides , Annals Internal Med, 130, 253-61. 

It may be of value to differentiate the indicating and monitoring uses of plants. Most reported work has used the indicator concept, with plant injury (symptoms) as indicative of a problem. Monitoring implies some degree of reliability. Several studies have attempted to use plant response as a monitor of pollution concentrations or doses, with variable but uncertain success. Plants could also be considered monitors if th gave a reliable index of the biologic effects on biologic systems of concern to man (crops, forests, animals, and man himself). The latter has not been seriously discussed. 

The obvious symptom of starvation is a loss of weight, which is most easily assessed by a decrease in the body mass index (BMI). Indeed, it is an excellent predictor of death from starvation. A value of BMI below about 13 in men and about 12 in women is not compatible with life. These values coincide with a loss of about 50% of lean body mass. The major causes of death from malnutrition in developed countries are pneumonia, other infections or heart failure. 

In CONCLUSION, lithium is universally accepted as a mood-stabilizing drug and an effective antimanic agent whose value is limited by its poor therapeutic index (i.e. its therapeutic to toxicity ratio). Neuroleptics are effective in attenuating the symptoms of acute mania but they too have serious adverse side effects. High potency typical neuroleptics appear to increase the likelihood of tardive dyskinesia. Of the less well-established treatments, carbamazepine would appear to have a role, particularly in the more advanced stages of the illness when lithium is less effective. 

Phenytoin is an anti-epileptic drug. Patients taking anti-epileptic drugs are advised to take the medicine routinely, as directed, to stabilise and to avoid epileptic attacks as much as possible. Phenytoin has a narrow therapeutic index so it is important to identify side-effects. It may cause blood disorders. Patients are therefore advised to report immediately any symptoms of bruising or unexplained bleeding. Visual symptoms as a result of phenytoin do not commonly occur. Their occurrence may indicate overdosage. 

In humans, early symptoms of intoxication may include headache, dizziness, nausea, vomiting, malaise, and myoclonic jerks of the limbs clonic and tonic convulsions and sometimes coma follow and may occur without the premonitory symptoms. A suicidal person who ingested 25.6mg/kg developed convulsions within 20 minutes that persisted recurrently until large amounts of barbiturates had been administered. Hematuria and azotemia occurred the day after ingestion and continued for 18 days. Liver function studies were within normal limits except for an elevated icterus index an electroencephalogram revealed generalized cerebral dysrhythmia, which returned to normal after 5 months. ... 

Adults - Take 9 mg once daily in the morning for up to 8 weeks. Swallow capsules whole do not chew or break. For recurring episodes of active Crohn disease, a repeat 8-week course of budesonide can be given. Following an 8-week course of treatment for active disease and once the patient s symptoms are controlled (Crohn Disease Activity Index less than 150), budesonide 6 mg is recommended once daily for maintenance of clinical remission for up to 3 months. If symptom control is still maintained at 3 months, an attempt to taper to complete cessation is recommended. Continued treatment with budesonide 6 mg for more than 3 months has not been shown to provide substantial clinical benefit. 

---